Global Hunter Maintains MDVN Buy Rating

Global Hunter has issued a report maintaining a Buy Rating on Medication Inc. MDVN. According to the report, “Although we believe the Street is not placing any value on this program, there is the potential for a favorable outcome based on the powering of the study. We continue to believe that the risk/reward profile supports owning this stock ahead of the HORIZON data as we view downside of at most $1 per share and upside of at least $3-$5. We continue to view the Alzheimer's program as a call option and MDV3100 as downside support.” MDVN has a $24 Price Target and closed at $20.11 on Friday.